Drug Trial Radar · NCT05256745
RAGE Inhibition to Decrease Cardiotoxicity in Women With Early Breast Cancer
Last checked: Nov 19, 2026Latest source record: Dec 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jun 6, 2023
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Georgetown UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Feb 25, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a pilot study to evaluate the effects of azeliragon to decrease cardiac toxicity from chemotherapy and the safety of azelirgaon when given with chemotherapy. The Investigators hypothesize that there will be no significant interaction with Azeliragon and chemotherapy and that targeting the RAGE pathway will decrease anthracycline related cardiotoxicity and chemotherapy related cognitive decline.
Conditions
- Cancer Related Cognitive Decline
- Non-metastatic Breast Cancer
Interventions
TTP488Drug
Each Azeliragon capsule is 5mg, and is to be taken in the morning with food as indicated in each cohort.
ddAC/ddTDrug
Dose dense doxorubicin plus cyclophosphamide followed by paclitaxel (ddAC/ddT) for 8 cycles, administered per USPI (Unites States Prescribing Information) Label
TCDrug
Docetaxel plus cyclophosphamide (TC) for 4-6 cycles, administered per USPI (Unites States Prescribing Information) Label
TCHPDrug
Docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP)for 6 cycles, administered per USPI (Unites States Prescribing Information) Label
Chemotherapy regimen that includes ddACDrug
can include: (1) weekly carboplatin + paclitaxel + pembrolizumab followed by pembrolizumab + dose dense doxorubicin and cyclophosphamide; (2) weekly carboplatin + paclitaxel followed by dose dense doxorubicin and cyclophosphamide; (3) weekly or dose dense paclitaxel followed by dose dense doxorubicin and cyclophosphamide, administered per USPI (Unites States Prescribing Information) Label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of unacceptable toxicityTime frame: 1 cycle (Cohort 1 and 4 each cycle is 14 days; Cohort 2 and 3 each cycle is 21 days)
- Incidence of severe AE graded according to the CTCAE v.5Time frame: 1 cycle (Cohort 1 and 4 each cycle is 14 days; Cohort 2 and 3 each cycle is 21 days)
- Incidence of chemotherapy dose interruption, dose modification, dose discontinuationTime frame: 1 cycle (Cohort 1 and 4 each cycle is 14 days; Cohort 2 and 3 each cycle is 21 days)
- Change in Troponin levelTime frame: Cohort 1 and 4: cycle 3 and cycle 4, day 1 and day 2 of 14 day cycle; Cohort 2 and 3:cycle 5 and cycle 6, day 1 and day 2 of 21 day cycle]
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Georgetown Lombardi Comprehensive Cancer Center
Washington D.C., District of Columbia · Recruiting
Medstar Washington Hospital Center
Washington D.C., District of Columbia · Recruiting
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.